towards therapy angelman syndrome targeting long non-coding rna 
angelman syndromeis single-gene disorder characterized intellectual disability developmental delay behavioural uniqueness speech impairment seizures ataxia caused maternal deficiency imprinted gene ube3a encoding e3 ubiquitin ligase- patients carry least one copy paternal ube3a intact silenced nuclear-localized long non-coding rna ube3a antisense transcript ube3a-ats- murine ube3a-ats reduction either transcription termination topoisomerase inhibition shown increase paternal ube3a expression despite clear understanding disease-causing event angelman syndrome potential harness intact paternal allele correct disease gene-specific treatment exists patients developed potential therapeutic intervention angelman syndrome reducing ube3a-ats antisense oligonucleotides asos aso treatment achieved specific reduction ube3a-ats sustained unsilencing paternal ube3a neurons vitro vivo partial restoration ube3a protein angelman syndrome mouse model ameliorated cognitive deficits associated disease although additional studies phenotypic correction needed developed sequence-specific clinically feasible method activate expression paternal ube3a allele 
